Omeros shows excellent cash conversion and a perfect 4-quarter earnings beat streak, but a weak Piotroski score, a steep drawdown, and heavy bearish options positioning reflect the binary risk inherent to a speculative biotech name.
Thesis pillars
- Excellent Cash Conversion→Stable
- Momentum Distribution Warning↑Improving
- Speculative Binary Biotech Risk→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 31, 2026
Omeros Corporation (OMER) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 1.53; Below-average business quality.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for... Read more
Sell if holding. Engine safety override at $17.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 1.53; Below-average business quality. Chart setup: RSI 43 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Omeros Corporation
Latest news
- NEWS Omeros Corp (OMER) Hits 52-Week High as Cantor Fitzgerald Upgrades on Yartemlea Sales Outlook - GuruFocus — GuruFocus positive
- NEWS Omeros Corp (OMER) Hits 52-Week High as Cantor Fitzgerald Upgrades on Yartemlea Sales Outlook - gurufocus.com — gurufocus.com positive
- NEWS NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today? - Asianet New — Asianet Newsable positive
- NEWS NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today? - newsable.as — newsable.asianetnews.com positive
- NEWS Omeros Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com — marketscreener.com positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYARTEMLEA10-K Item 1A: 'YARTEMLEA is our only commercialized product and was approved by FDA for commercial sale in the United States in December 2025.'
- HIGHSupplierLonza10-K Item 1: 'we entered into a master services agreement with Lonza Biologics Tuas Pte. Ltd. ("Lonza") for the commercial production of YARTEMLEA'
- HIGHSupplierVetter10-K Item 1: 'Vetter has agreed to aseptically fill YARTEMLEA in vials for clinical or commercial use'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Volatile — 5.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.88: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 1.53; Below-average business quality. Chart setup: RSI 43 mid-range, Bollinger mid-band. Prior stop was $16.63. Score 5.3/10, moderate confidence.
Analyst target: $23.38 (+30.7% upside). Prior stop was $16.63. Stop-loss: $16.63.
Concentration risk — Product: YARTEMLEA; Concentration risk — Supplier: Lonza; Risk below floor (1.3 < 2.5).
Omeros Corporation trades at a P/E of 14.7 (forward 14.5). TrendMatrix value score: 6.5/10. Verdict: Sell.
10 analysts cover OMER with a consensus score of 4.1/5. Average price target: $28.
What does Omeros Corporation do?Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule...
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.